Affinity Asset Advisors, LLC 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Affinity Asset Advisors, LLC disclosed 104 US equity positions worth $2.0bn in its Q2 2026 13F filing. The largest position was ROIV at 6.5% of the reported book, followed by APGE and SYRE. Against the Q1 2026 filing, it opened 3 new positions, added to 24 and reduced 15 among the top 50 holdings.
What did Affinity Asset Advisors, LLC own in Q2 2026? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | ROIV ROIVANT SCIENCES LTD | Healthcare | 6.5% | $132.7m | 3,750,000 | 34% | added |
| 2 | APGE APOGEE THERAPEUTICS INC | Healthcare | 6.4% | $131.0m | 987,000 | -23% | reduced |
| 3 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 5.6% | $113.6m | 1,279,134 | 0% | held |
| 4 | XENE XENON PHARMACEUTICALS INC | Healthcare | 4.7% | $96.3m | 1,595,000 | -5% | reduced |
| 5 | ERAS ERASCA INC | Healthcare | 4.7% | $96.2m | 5,250,000 | -2% | reduced |
| 6 | INSM INSMED INC | Healthcare | 3.4% | $69.3m | 650,000 | 35% | added |
| 7 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 3.0% | $61.9m | 185,000 | 9% | added |
| 8 | ALKS ALKERMES PLC | Healthcare | 2.9% | $58.9m | 1,125,000 | -17% | reduced |
| 9 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 2.7% | $56.2m | 590,000 | 18% | added |
| 10 | ANAB ANAPTYSBIO INC | Healthcare | 2.7% | $55.8m | 826,109 | -12% | reduced |
| 11 | AVTX AVALO THERAPEUTICS INC | Healthcare | 2.6% | $53.6m | 2,900,000 | 116% | added |
| 12 | CYTK CYTOKINETICS INC | Healthcare | 2.3% | $46.9m | 550,000 | -21% | reduced |
| 13 | RVMD REVOLUTION MEDICINES INC | Healthcare | 2.3% | $46.8m | 250,000 | 150% | added |
| 14 | ABVX ABIVAX SA | Healthcare | 2.2% | $44.0m | 330,000 | -19% | reduced |
| 15 | TRAX FIRST TRACKS BIOTHERAPEUTICS | 2.0% | $40.9m | 2,032,012 | – | new | |
| 16 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 1.9% | $39.0m | 400,000 | 14% | added |
| 17 | STRO SUTRO BIOPHARMA INC | Healthcare | 1.9% | $38.9m | 1,172,487 | 10% | added |
| 18 | NUVALENT INC | 1.7% | $34.0m | 275,000 | -8% | reduced | |
| 19 | TRVI TREVI THERAPEUTICS INC | Healthcare | 1.6% | $33.6m | 1,800,172 | -10% | reduced |
| 20 | OVID OVID THERAPEUTICS INC | Healthcare | 1.3% | $27.3m | 10,144,562 | -5% | reduced |
| 21 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 1.3% | $27.0m | 5,807,611 | 15% | added |
| 22 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.3% | $26.0m | 700,000 | 40% | added |
| 23 | BLTE BELITE BIO INC | Healthcare | 1.2% | $25.4m | 165,000 | 154% | added |
| 24 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 1.2% | $25.4m | 500,000 | -15% | reduced |
| 25 | FBRX FORTE BIOSCIENCES INC | 1.2% | $24.3m | 1,145,391 | 13% | added | |
| 26 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.1% | $23.5m | 967,620 | 0% | held |
| 27 | ANRO ALTO NEUROSCIENCE INC | Healthcare | 1.1% | $22.4m | 850,000 | 70% | added |
| 28 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 1.1% | $21.5m | 40,000 | -27% | reduced |
| 29 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 1.0% | $21.1m | 172,125 | 0% | held |
| 30 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.0% | $20.2m | 750,000 | 0% | held |
| 31 | RLAY RELAY THERAPEUTICS INC | Healthcare | 1.0% | $19.6m | 1,050,000 | 162% | added |
| 32 | SGMT SAGIMET BIOSCIENCES INC | Healthcare | 0.9% | $19.3m | 2,497,864 | 188% | added |
| 33 | JBIO JADE BIOSCIENCES INC | Healthcare | 0.9% | $18.7m | 840,350 | 31% | added |
| 34 | COGT COGENT BIOSCIENCES INC | Healthcare | 0.9% | $17.4m | 450,000 | -40% | reduced |
| 35 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 0.8% | $17.0m | 300,000 | 0% | held |
| 36 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 0.8% | $15.9m | 875,760 | 12% | added |
| 37 | SVRA SAVARA INC | Healthcare | 0.8% | $15.5m | 2,512,153 | 0% | held |
| 38 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 0.7% | $14.9m | 400,000 | – | new |
| 39 | CATX PERSPECTIVE THERAPEUTICS INC | 0.7% | $14.4m | 4,214,582 | 33% | added | |
| 40 | ODYSSEY THERAPEUTICS INC | 0.7% | $14.3m | 766,346 | – | new | |
| 41 | COGENT BIOSCIENCES INC | 0.7% | $13.7m | 11,000,000 | 57% | added | |
| 42 | HELIX ACQUISITION CORP III | 0.7% | $13.3m | 1,250,000 | 0% | held | |
| 43 | EQ EQUILLIUM INC | 0.6% | $13.1m | 4,100,000 | 234% | added | |
| 44 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 0.6% | $12.7m | 148,013 | 48% | added |
| 45 | CLYM CLIMB BIO INC | Healthcare | 0.6% | $12.7m | 972,000 | 39% | added |
| 46 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 0.6% | $12.7m | 374,000 | -73% | reduced |
| 47 | MANE VERADERMICS INC | Healthcare | 0.6% | $12.3m | 100,000 | 43% | added |
| 48 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 0.6% | $12.2m | 150,000 | -25% | reduced |
| 49 | OMEROS CORP | 0.6% | $12.2m | 6,525,000 | 0% | held | |
| 50 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.6% | $11.9m | 1,750,000 | 75% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.